Methylphenidate: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
MDElliottMD (talk | contribs) parser-claude: targeted corrections, 7 fix(es) (stale FDA Cat C; house-rule banned terms) |
||
| Line 3: | Line 3: | ||
| brand = Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR | | brand = Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR | ||
| structure = Methylphenidate.svg | | structure = Methylphenidate.svg | ||
| classes = Psychostimulant | | classes = Psychostimulant, NDRI | ||
| mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET) | | mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET) | ||
| uses = ADHD, narcolepsy | | uses = ADHD, narcolepsy | ||
| Line 12: | Line 12: | ||
| halflife = 2–3 h (parent compound) | | halflife = 2–3 h (parent compound) | ||
| bioavailability = ~30% (high first-pass) | | bioavailability = ~30% (high first-pass) | ||
| pregnancy = | | pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. | ||
| legal = Schedule II | | legal = Schedule II | ||
| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system | | intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need. | ||
| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect. | | pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect. | ||
| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce. | | pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce. | ||
| Line 54: | Line 54: | ||
* '''Antihypertensives''', methylphenidate's pressor effect may partially antagonize | * '''Antihypertensives''', methylphenidate's pressor effect may partially antagonize | ||
* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants), additive cardiovascular effects | * '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants), additive cardiovascular effects | ||
* ''' | * '''Neuroleptics''', pharmacologic antagonism (each may partially block the other's effects) | ||
* '''Alcohol''', may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism | * '''Alcohol''', may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism | ||
* '''Caffeine''', additive | * '''Caffeine''', additive psychostimulant and anxiogenic effects | ||
Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s, a clinical advantage over amphetamine when polypharmacy is a concern. | Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s, a clinical advantage over amphetamine when polypharmacy is a concern. | ||
<pharmaInteractions/> | <pharmaInteractions/> | ||
| pregnancy_details = | | pregnancy_details = Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies, interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring. | ||
| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use | | monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use | ||
* Consider ECG if cardiac risk factors are present | * Consider ECG if cardiac risk factors are present | ||
| Line 71: | Line 71: | ||
* Eat regular meals despite appetite suppression; weigh periodically. | * Eat regular meals despite appetite suppression; weigh periodically. | ||
* Stay well-hydrated. | * Stay well-hydrated. | ||
* Do not combine with significant alcohol or other | * Do not combine with significant alcohol or other psychostimulants. | ||
* Do not share or sell, Schedule II controlled substance; serious legal and clinical consequences. | * Do not share or sell, Schedule II controlled substance; serious legal and clinical consequences. | ||
* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics. | * Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics. | ||